168 related articles for article (PubMed ID: 27000270)
1. [Earlier value assessment of pharmaceutical products and medical science].
Selbmann HK
Nervenarzt; 2016 Apr; 87(4):353-5. PubMed ID: 27000270
[No Abstract] [Full Text] [Related]
2. [Effect of the German Act on the reform of the market for medicinal products (AMNOG) on the quality of neurological and psychiatric treatment].
Hamer H; Meyer-Lindenberg A
Nervenarzt; 2016 Apr; 87(4):351-2. PubMed ID: 27025218
[No Abstract] [Full Text] [Related]
3. [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].
Gründer G
Nervenarzt; 2016 Apr; 87(4):356-66. PubMed ID: 26983820
[TBL] [Abstract][Full Text] [Related]
4. [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
Broich K; Löbker W; Schulte A; Beinlich P; Müller T
Nervenarzt; 2016 Apr; 87(4):376-85. PubMed ID: 27003322
[TBL] [Abstract][Full Text] [Related]
5. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
Bittner S; Meuth SG
Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
[TBL] [Abstract][Full Text] [Related]
6. [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].
Strzelczyk A; Hamer HM
Nervenarzt; 2016 Apr; 87(4):386-93. PubMed ID: 26927680
[TBL] [Abstract][Full Text] [Related]
7. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
Dittmann RW
Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
[TBL] [Abstract][Full Text] [Related]
8. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
9. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
Purnhagen KP
Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
[No Abstract] [Full Text] [Related]
10. Outcomes assessment in health care reform: promise and limitations.
Mariner WK
Am J Law Med; 1994; 20(1-2):37-57. PubMed ID: 7801980
[No Abstract] [Full Text] [Related]
11. An insider's perspective: defense of the pharmaceutical industry's marketing practices.
Johar K
Albany Law Rev; 2012-2013; 76(1):299-334. PubMed ID: 23577377
[No Abstract] [Full Text] [Related]
12. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
13. Pharmaceuticals and medical devices: FDA oversight.
Berry MD
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
[No Abstract] [Full Text] [Related]
14. Applying market power--the BHCAG is flexing its muscle. Business Health Care Action Group.
Allen T
Minn Med; 1994 Dec; 77(12):6-7, 52. PubMed ID: 7823884
[No Abstract] [Full Text] [Related]
15. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
16. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
17. [The therapy allergens ordinance ("Therapieallergene-Verordnung"). Background and effects].
Englert L; May S; Kaul S; Vieths S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):351-7. PubMed ID: 22373848
[TBL] [Abstract][Full Text] [Related]
18. Raising the bar for market authorisation of new drugs.
Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
[No Abstract] [Full Text] [Related]
19. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
[TBL] [Abstract][Full Text] [Related]
20. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
[Next] [New Search]